Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage II/IIIa NSCLC

Condition:   Potentially Resectable Stage II/IIIa NSCLC
Intervention:   Drug: durvalumab
Sponsor:   Yonsei University
Not yet recruiting

https://ift.tt/2Iz3gOT